Evidence demonstrated that without a secondary therapy following BCR, about 30% of patients underwent clinically manifested distant metastasis, and 19-27% of patients may suffer prostate-cancer specific mortality within 10 years 37, 38. The gene discussed is BCR; the disease is prostate cancer.